Premium
mi RNA in hepatocellular carcinoma
Author(s) -
Morishita Asahiro,
Masaki Tsutomu
Publication year - 2015
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12386
Subject(s) - microrna , hepatocellular carcinoma , pathogenesis , cancer research , cancer , medicine , bioinformatics , gene , biology , oncology , genetics
Hepatocellular carcinoma ( HCC ) is the third leading cause of cancer deaths worldwide. Despite improvements in HCC therapy, the prognosis for HCC patients remains poor due to a high incidence of recurrence. An improved understanding of the pathogenesis of HCC development would facilitate the development of more effective outcomes for the diagnosis and treatment of HCC at earlier stages. mi RNA are small, endogenous, non‐coding, ss RNA that are 21–30 nucleotides in length and modulate the expression of various target genes at the post‐transcriptional and translational levels. Aberrant expression of mi RNA is common in various human malignancies and modulates cancer‐associated genomic regions or fragile sites. As for the relationship between mi RNA and HCC , several studies have demonstrated that the aberrant expression of specific mi RNA can be detected in HCC cells and tissues. However, little is known about the mechanisms of mi RNA ‐related cell proliferation and development. In this review, we summarize the central and potential roles of mi RNA in the pathogenesis of HCC and elucidate new possibilities that may be useful as diagnostic and prognostic markers, as well as novel therapeutic targets in HCC .